The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
Open accessAbstract
BACKGROUND: The amyloid fibril deposits that cause systemic amyloidosis always contain the nonfibrillar normal plasma protein, serum amyloid P component (SAP). The drug (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC) efficiently depletes SAP from the plasma but leaves some SAP in amyloid deposits that can be specifically targeted by therapeutic IgG anti-SAP antibodies. In murine amyloid A type amyloidosis, the binding of these antibodies to the residual SAP in amyloid deposits activates complement and triggers the rapid clearance of amyloid by macrophage-derived multinucleated giant cells. METHODS: We conducted an open-label, single-dose-escalation, phase 1 trial involving 15 patients with systemic amyloidosis. After first using CPHPC to deplete circulating SAP, we infused a fully humanized monoclonal IgG1 anti-SAP antibody. Patients with clinical evidence of cardiac involvement were not included for safety reasons. Organ function, inflammatory markers, and amyloid load were monitored. RESULTS: There were no serious adverse events. Infusion reactions occurred in some of the initial recipients of larger doses of antibody; reactions were reduced by slowing the infusion rate for later patients. At 6 weeks, patients who had received a sufficient dose of antibody in relation to their amyloid load had decreased liver stiffness, as measured with the use of transient elastography. These patients also had improvements in liver function in association with a substantial reduction in hepatic amyloid load, as shown by means of SAP scintigraphy and measurement of extracellular volume by magnetic resonance imaging. A reduction in kidney amyloid load and shrinkage of an amyloid-laden lymph node were also observed. CONCLUSIONS: Treatment with CPHPC followed by an anti-SAP antibody safely triggered clearance of amyloid deposits from the liver and some other tissues. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01777243.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moon, J. C., Messroghli, D. R., Kellman, P., Piechnik, S. K., Robson, M. D., Ugander, M., Gatehouse, P. D., Arai, A. E., Friedrich, M. G., Neubauer, S., et al. (2013) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-15-92 · Cited by 1,136
Self-citationAcute viral hepatitis increases liver stiffness values measured by transient elastography
Arena, U., Vizzutti, F., Corti, G., Ambu, S., Stasi, C., Bresci, S., Moscarella, S., Boddi, V., Petrarca, A., Laffi, G., et al. (2008) · Hepatology · doi:10.1002/hep.22007 · Cited by 754
Self-citationPepys, M. B. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131243 · Cited by 559
Self-citationTargeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
Self-citationEvaluation of Systemic Amyloidosis by Scintigraphy with123I-Labeled Serum Amyloid P Component
Hawkins, P. N., Lavender, J. P., & Pepys, M. B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008233230803 · Cited by 533
Self-citationAntibodies to human serum amyloid P component eliminate visceral amyloid deposits
Bodin, K., Ellmerich, S., Kahan, M. C., Tennent, G. A., Loesch, A., Gilbertson, J. A., Hutchinson, W. L., Mangione, P. P., Gallimore, J. R., Millar, D. J., et al. (2010) · Nature · doi:10.1038/nature09494 · Cited by 341
Self-citationBanypersad, S. M., Sado, D. M., Flett, A. S., Gibbs, S. D. J., Pinney, J. H., Maestrini, V., Cox, A. T., Fontana, M., Whelan, C. J., Wechalekar, A. D., et al. (2013) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.978627 · Cited by 335
Self-citation(1979) · PubMed Central · Cited by 271
Amyloid P-component is a constituent of normal human glomerular basement membrane.
Dyck, R. F., Lockwood, C. M., Kershaw, M., McHugh, N., Duance, V. C., Baltz, M. L., & Pepys, M. B. (1980) · The Journal of experimental medicine · doi:10.1084/jem.152.5.1162 · Cited by 216
Self-citationAmyloid P component is located on elastic fibre microfibrils in normal human tissue
Breathnach, S. M., Melrose, S. M., Bhogal, B., de Beer, F. C., Dyck, R. F., Tennentt, G., Black, M. M., & Pepys, M. B. (1981) · Nature · doi:10.1038/293652a0 · Cited by 192
Self-citationAmyloid P component. A critical review
Pepys, M. B., Booth, D. R., Hutchinson, W. L., Gallimore, J. R., Collins, I. M., & Hohenester, E. (1997) · Amyloid · doi:10.3109/13506129709003838 · Cited by 181
Self-citationOxford Textbook of Medicine , 4th Edn
Hunter, J. M. (2003) · British Journal of Anaesthesia · doi:10.1093/bja/aeg576 · Cited by 164
Gillmore, J. D., Tennent, G. A., Hutchinson, W. L., Gallimore, J. R., Lachmann, H. J., Goodman, H. J. B., Offer, M., Millar, D. J., Petrie, A., Hawkins, P. N., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08036.x · Cited by 138
Self-citationPathogenetic mechanisms of amyloid A amyloidosis
Simons, J. P., Al‐Shawi, R., Ellmerich, S., Speck, I., Aslam, S., Hutchinson, W. L., Mangione, P. P., Disterer, P., Gilbertson, J. A., Hunt, T., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306621110 · Cited by 137
Self-citationLovat, L. B., Persey, M. R., Madhoo, S., et al. (1998) · Gut · doi:10.1136/gut.42.5.727 · Cited by 133
Hawkins, P. N., Wootton, R., & Pepys, M. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114917 · Cited by 102
Self-citationSerum amyloid P component in chronic renal failure and dialysis.
Nelson, S. R., Tennent, G., Sethi, D., Gower, P., Ballardie, F. W., Amatayakul-Chantler, S., & Pepys, M. (1991) · Clinica chimica acta; international journal of clinical chemistry · doi:10.1016/0009-8981(91)90090-y · Cited by 91
Self-citationMolecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component
Kolstoe, S. E., Ridha, B. H., Bellotti, V., Wang, N., Robinson, C. V., Crutch, S. J., Keir, G., Kukkastenvehmas, R. H., Gallimore, J. R., Hutchinson, W. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902640106 · Cited by 67
Self-citationBandula, S., Banypersad, S. M., Sado, D., Flett, A. S., Punwani, S., Taylor, S. A., Hawkins, P. N., & Moon, J. C. (2013) · Radiology · doi:10.1148/radiol.13121889 · Cited by 59
Self-citationNon-invasive detection of hepatic amyloidosis: FibroScan, a new tool
Loustaud-Ratti, V., Cypierre, A., Rousseau, A., Yagoubi, F., Abraham, J., Fauchais, A. L., Carrier, P., Lefebvre, A., Bordessoule, D., Vidal, E., et al. (2011) · Amyloid · doi:10.3109/13506129.2010.543443 · Cited by 49
Liver AL amyloidosis as a possible cause of high liver stiffness values
Lanzi, A., Gianstefani, A., Mirarchi, M. G., Pini, P., Conti, F., & Bolondi, L. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283309d5b · Cited by 43
Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis
Sahota, T., Berges, A., Barton, S., Cookson, L., Zamuner, S., & Richards, D. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.15 · Cited by 19
Self-citationPepys, M. B., & Hawkins, P. N. (2010) · Oxford University Press eBooks · doi:10.1093/med/9780199204854.003.121203 · Cited by 1
Self-citation
Cited by
Messroghli, D. R., Moon, J. C., Ferreira, V. M., Grosse-Wortmann, L., He, T., Kellman, P., Mascherbauer, J., Nezafat, R., Salerno, M., Schelbert, E. B., et al. (2016) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-017-0389-8 · Cited by 1,727
Self-citationTransthyretin Amyloid Cardiomyopathy
Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W., & Maurer, M. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.003 · Cited by 1,112
Wechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
Self-citationA new staging system for cardiac transthyretin amyloidosis
Gillmore, J. D., Damy, T., Fontana, M., Hutchinson, M., Lachmann, H. J., Martinez-Naharro, A., Quarta, C. C., Rezk, T., Whelan, C. J., Gonzalez-Lopez, E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx589 · Cited by 776
Self-citationKittleson, M. M., Maurer, M. S., Ambardekar, A. V., Bullock-Palmer, R. P., Chang, P. P., Eisen, H. J., Nair, A. P., Nativi-Nicolau, J., Ruberg, F. L., & On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology (2020) · Circulation · doi:10.1161/cir.0000000000000792 · Cited by 756
Metadata
- Authors
- Richards, D. B., Cookson, L. M., Berges, A. C., Barton, S. V., Lane, T., Ritter, J. M., Fontana, M., Moon, J. C., Pinzani, M., Gillmore, J. D., Hawkins, P. N., & Pepys, M. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-09-17
- Volume
- 373
- Issue
- 12
- Pages
- 1106-1114
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2282508430
- Cited by
- 378
- References
- 23
- FWCI
- 20.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.